See our profile
Please use the form below to:
  • Send us your feedback or suggestion for a story
  • Contribute an article
  • Send a news snippet, gossip to The Grapevine
  • Have someone contact you about advertising on the site
Name:
Company:
Email:
Comment:
Contact details

Silicon Fen Business Report
Midsummer Court
Manhattan Drive
Cambridge
CB4 1JX

editorATsiliconfenbusiness.com

Previous articles
Market likes what it sees as Alyzyme enters pivotal period
BioProgress makes big dent in losses in 1H06; on track for break even
Amino Technologies sees solid revenue growth but profit hit by weaker dollar
Brady gains 10% as it signs up new customer, reports cash pile
AVEVA 1H07 revenue, pretax profit maintains hectic pace of growth thanks to R&D spend, bouyant markets
Wellcome’s Sanger Institute to focus research on genetics
Aveva big winner in 2006; Plasmon, Tadpole go backwards
Qualcom buys stake in ip.access
Phytopharm’s losses widen; major programmes on track
Cybit starts year ‘extremely well’; sales more than double
Subscribe

 

Corporate profiles

 • Alizyme


Timothy McCarthy
Chief Executive Officer


Alizyme plc is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focused on obesity and related diseases, such as diabetes, and on gastrointestinal disorders including irritable bowel syndrome, inflammatory

[Alizyme's profile]


Top20 Index




Currently: 111.35